| 000 | 00927 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250518082800.0 | ||
| 264 | 0 | _c20201007 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a1432-1041 | ||
| 024 | 7 |
_a10.1007/s00228-020-02839-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBoone, N W | |
| 245 | 0 | 0 |
_aLess is more: a cost benefit analysis of a changed posology for nivolumab. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cMay 2020 |
||
| 300 |
_a739-740 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNivolumab _xadministration & dosage |
| 700 | 1 | _avan Bodegraven, A A | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 76 _gno. 5 _gp. 739-740 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00228-020-02839-7 _zAvailable from publisher's website |
| 999 |
_c30572085 _d30572085 |
||